Dispatch Bio Showcases Clinical-Stage Flare Platform at AACR IO26

A LinkedIn post from Dispatch Bio highlights that co‑founder and Chief Platform Officer Lexus Johnson, PhD, is presenting a poster at AACR IO26 on the company’s clinical‑stage Flare platform. The post describes Flare as a systemically delivered, tumor‑specific viral approach intended to “paint” a universal synthetic antigen on tumor cells.

According to the post, this design aims to improve recognition by T cells while reshaping the immunosuppressive tumor microenvironment in solid tumors. For investors, this visibility at a major immuno‑oncology forum may indicate continued progress of Dispatch Bio’s platform toward broader solid tumor applications, potentially enhancing its profile for future partnerships or financing.